Whole-exome sequencing in children with dyslexia identifies rare variants in *CLDN3* and ion channel genes

Krzysztof Marianski[1], Joel B. Talcott[2], John Stein[3], Anthony P. Monaco[4], Simon E. Fisher[5,6], Dorothy V.M. Bishop[7], Dianne F. Newbury[8,9] and Silvia Paracchini[1]

[1] *School of Medicine, University of St Andrews, St Andrews, UK*

[2] *Institute of Health and Neurodevelopment, College of Health and Life Sciences, Aston University, Birmingham, UK*

[3] *Department of Physiology, University of Oxford, Oxford, UK*

[4] *Office of the President emeritus, Tufts University, Medford, MA, USA*

[5] *Language and Genetics Department, Max Planck Institute for Psycholinguistics, Nijmegen, Netherlands*

[6] *Donders Institute for Brain, Cognition and Behaviour, Radboud University, Nijmegen, Netherlands*

[7] *Department of Experimental Psychology, University of Oxford, Oxford, UK*

[8] *Department of Medical and Biological Sciences, Oxford Brookes University, UK*

[9] *Centre for Human Genetics, University of Oxford, Oxford, UK*

Correspondence to Silvia Paracchini sp58@st-andrews.ac.uk

Abstract

Dyslexia is a specific difficulty in learning to read that affects 5-10% of school-aged children and is strongly influenced by genetic factors. While previous studies have identified common genetic variants associated with dyslexia, the role of rare variants has only recently begun to emerge from pedigree studies and has yet to be systematically tested in larger cohorts. Here, we present a whole-exome sequencing (WES) study of 53 individuals with dyslexia, followed by replication analysis in 38 cases with reading difficulties and 82 controls assessed with reading measures. Our stringent bioinformatics filtering strategy highlighted five brain-expressed genes carrying rare variants: *CACNA1D*, *CACNA1G*, *CLDN3*, *CNGB1,* and *CP*. Notably, a specific variant (7-73769649-G-A) in the *CLDN3* gene was identified in six independent cases, showing a four-fold higher frequency compared to population reference datasets. *CACNA1D* and *CACNA1G* encode subunits of voltage-gated calcium channels (VGCC) expressed in neurons, and variants in both genes have been implicated in neurodevelopmental disorders such as autism spectrum disorder (ASD) and epilepsy. Segregation analysis in available family members were consistent with patterns of dominant inheritance with variable expressivity. In total, high-impact variants in the five genes of interest were found in 26% (N = 14) of individuals of the discovery cohort. Overall, our findings support the involvement of rare variants in developmental dyslexia and indicate that larger WES studies may uncover additional associated genes.

Introduction

Dyslexia is a neurodevelopmental condition characterised by a specific difficulty in learning to read, occurring in the absence of other causes such as sensory or neurological problems or lack of educational opportunity (1). Regardless of culture and spoken-language, dyslexia affects 5%–10% of children, with a male: female ratio ranging from about 3:1 to 5:1 (2), and often co-occurs with other neurodevelopmental conditions such as developmental language disorders (DLD) and attention deficit hyperactivity disorder (ADHD) (3,4). A strong genetic component for dyslexia is supported by twin studies, which have shown heritability

estimates of up to 70%. Moreover, having a first degree relative with dyslexia is the most consistently identified risk factor (5). These observations have motivated molecular studies, but the identification of specific genes has, until recently, been hindered by difficulties in assembling sufficiently powered sample sizes. Lack of national screening programs and heterogeneous assessment and diagnostic criteria pose challenges in recruiting study participants and combining them across studies (1). Initial molecular studies highlighted a handful of genes, including *ROBO1, DCDC2, KIAA0319* and *DYX1C1* (6). However, associations to these genes did not consistently replicate (1).

A breakthrough was made possible by a large (51,800 cases and 1,087,070 controls) genome-wide association study (GWAS) conducted with self-reported dyslexia diagnoses by customers of the direct-to-consumer company 23andMe (7). This study identified 42 independently statistically significant associated loci. About half of these had previously been associated with cognitive phenotypes, while the other half suggested effects more specific to dyslexia. A gene-based analysis reported association with 173 genes. This study also facilitated the generation of dyslexia polygenic scores, which showed significant associations with the reading-related measures available for some cohorts of the GenLang consortium (https://www.genlang.org/), an international project aimed at dissecting the genetics of language-related traits, including reading abilities. An independent quantitative meta-GWAS of reading- and language-related measures in the GenLang cohorts (N ~34,000) identified only a single genome-wide significant locus but highlighted significant genetic correlations across language-related cognitive domains and traits derived from neuroimaging data (8). The SNP-based heritability from these GWAS efforts ranged between 0.13 and 0.26. Although larger GWAS are expected to identify additional common variants associated with dyslexia, it is likely that rare variants, *e.g.* those with a minor allele frequency (MAF) < 1%, will also play a role.

Whole-exome (WES) and whole-genome sequencing (WGS) studies have demonstrated the role of rare variants in most complex traits (9) including for neurodevelopmental conditions like autism spectrum disorder (ASD) (10), schizophrenia (11), bipolar disorder (12) and childhood apraxia of speech (CAS) (13–15). Rare variants have been reported also for conditions that frequently co-occur with dyslexia, such as ADHD (16) and language

impairment (17–19). Rare variant analyses and WES screenings focussing specifically on dyslexia are limited. *DYX1C1*, the first risk gene reported as a dyslexia candidate was found to be disrupted by a translocation in one individual (20). Segregation analyses in large pedigrees suggested the role of variants in the *CEP63* (21), *NCAN* (22), and *SEMA3C* (23) genes. Large population-based cohorts like the UK Biobank, for which WES data have been generated at scale, are not well-suite for genetic studies of dyslexia because data on dyslexia diagnosis are not reliable and reading-related measures have not been collected (1). Furthermore, it has been shown that rare variants detected in clinical cohorts might not show signals in population samples because of incomplete penetrance *(i.e.* when not all individuals with the variant exhibit the trait) or variable expressivity (when different degrees of a phenotype are associated with the variant) (24).

In the current proof-of-principle WES study, we analysed 53 unrelated individuals with dyslexia. Replication analysis was performed in an independent cohort of 38 cases with reading difficulties (RD) and 82 typically developing (TD) controls, assessed with the same quantitative test as part of a twin study on language-related problems and co-occurring conditions. Our findings highlight rare variants in five genes *CACNA1G, CACNA1D, CLDN3, CNGB1,* and *CP*. Notably, a specific *CLDN3* variant was identified in six independent cases and was not observed in the controls. The availability of family members and quantitative assessments facilitated segregation analysis and enabled the evaluation of the impact of variants on reading-related measures.

Material and Methods

Discovery cohort

We analysed a discovery sample of 53 unrelated cases selected from two existing cohorts recruited for genetic studies of dyslexia and which have been previously described (Table 1) (25). The first cohort includes 290 families (689 siblings, 580 parents), most with at least one child diagnosed with dyslexia and a second child presenting reading difficulties. The second cohort comprises 592 singletons with dyslexia or reading problems. Both cohorts were recruited in the South of England at Dyslexia Research Centre clinics in Oxford and Reading or the Aston Dyslexia and Development Unit in Birmingham. All children (probands and their

siblings) were individually assessed with the following core tasks: single-word reading (SWR) and single-word spelling accuracy (SPELL)(26), single non-word reading (NWR) (27), phonological awareness (PA) (28), irregular word reading (IWR) (27), orthographic coding (ORTH) (29), as well as measures of verbal (VIQ) and performance (PIQ) IQ (30) (See supplementary Table 1). Parents in the family cohort were not formally assessed but some of them provided information about their own and their family's history of dyslexia or reading problems by questionnaire during an interview. In both cohorts, probands were excluded if they had been formally diagnosed with co-occurring developmental conditions such as language impairment, autism or ADHD.

For this study, individual cases were prioritised based on low SWR scores and availability of a high-quality DNA sample. In total, 53 unrelated cases were selected, 33 from the family cohort and 20 from the singleton cohort. WES data were also generated for available family members (N = 14) of variant carriers in the top five genes for segregation analysis.

The study was approved by the Oxfordshire Psychiatric Research Ethics Committee and the Aston University Ethics Committee, with informed consent obtained from all the participants and/or their caregivers.

Replication and control cohorts

The replication and control cohorts were derived from a UK twin cohort (N = 194 twin pairs) recruited to study language difficulties (31). From this cohort, replication cases and controls were selected based on the following criteria.

Replication cases with reading difficulties (RD) were required to have a PIQ above or equal to -1 SD and at least one score more than 1 SD below the expected level on any of the following tests: single word reading (SWR), non-word reading (NWR) (32), text reading accuracy (ACC), comprehension (COMP) or reading rate (RR) from the NARA-II (33). See Supplementary Table 1 for more details on the tests.

Typically developing (TD) controls were selected based on a PIQ of no more than 1 SD below the expected level for their age and a SWR score above the mean. Children with a Development and Well-Being Assessment (DAWBA) diagnosis of ASD (34) were removed from both groups.

If both twins in a pair met the criteria for inclusion, one twin was randomly selected for the study. This process resulted in a replication group of 38 cases with RD and 82 TD controls with good reading scores. Descriptive statistics and mean phenotypic scores for these two groups are shown in Table 1. WES and phenotypic data were available for their twin siblings for follow up analyses. The study was approved by the Berkshire NHS Research Ethics Committee.

Siblings and family members of the dyslexia and RD cases were assigned to a category of mild reading difficulties if they scored below 1 SD on at least one reading measure or had an average score across all reading measures at least 0.25 SD below the mean.

Bioinformatics analysis

WES data for all samples were generated using Illumina technology (NovaSeq 6000, Q30 ≥ 80%, with 50X coverage). Raw sequences were trimmed using Trimmomatic (35). Trimmed reads were mapped to the human reference genome (GRCh38) using bwa-mem (https://github.com/lh3/bwa). Picard tools (http://broadinstitute.github.io/picard/) were used for read-groups replacement, removal of PCR duplicates, and base recalibration. The pre-processed reads were indexed using SAMtools (https://www.htslib.org/) and called with DeepVariant v1.4.0 (36). VCF files were annotated with ANNOVAR (37) to identify high-impact variants.

In accordance with the ACMG guidelines (38), high-impact variants were defined as rare variants (PM2) predicted to damage protein function (PP3). Accordingly, variants were removed if they had a minor allele frequency (MAF) ≥ 1% (based on gnomAD v3.1.2 for Non-Finnish Europeans), or if they were annotated as synonymous, intronic or intergenic variants. To be retained, variants had to be predicted as damaging by all five predictive algorithms (SIFT, PolyPhen2, LRT, MutationTaster and FATHMM) or already annotated as pathogenic or likely pathogenic in ClinVar for any disorders (https://www.ncbi.nlm.nih.gov/clinvar/). Genes were selected as candidates if high-impact variants were detected in three or more independent cases in the discovery cohort (in accordance with Genomics England guidelines (https://panelapp.genomicsengland.co.uk/). To warrant further follow-up, the gene also had

to carry at least one high-impact variant in the RD replication cases and no such variants in the TD replication controls.

Genomic localisation of the variants of interest was based on UniProt and InterPro data. Exonic locations were accessed from UCSC Table Browser hg38.refGene.

Post-WES analyses

The overlap between the genes identified as candidates in the discovery cohort and those found to be associated in the dyslexia GWAS by Doust et al. (2022) was tested with the GeneOverlap package in R (https://rdrr.io/bioc/GeneOverlap/).

Gene-set enrichment was performed in FUMA (GENE2FUNC tool https://fuma.ctglab.nl/) using Gene Ontology classifications and expression data from GTExv8.0. A list of unique genes was compared against all protein-coding genes, with Benjamini-Hochberg (false discovery rate, FDR) correction applied for multiple testing. Enrichment within brain regions at different developmental stages was tested using the BrainSpan dataset.

Brain expression levels for top genes were extracted from GTEXv8.0 (39) and reported as the maximum observed normalised gene expression across 13 brain regions: amygdala, anterior cingulate cortex, basal ganglia, cerebellar hemisphere, cerebellum, cortex, frontal cortex, hippocampus, hypothalamus, nucleus accumbens, putamen, spinal cord, and substantia nigra.

Results

WES analysis in this discovery cohort (N=53) identified 580 high-impact variants (as defined in Methods) across 512 genes (Supplementary Table 2). On average, each individual carried 11 high-impact variants.

To investigate overlaps with previous findings from analyses of common variants, we compared the identified genes with the 173 genes reported in gene-based analysis of the

dyslexia GWAS by Doust and colleagues (7). There was no statistically significant overlap (P = 0.16) and only seven of the GWAS-identified genes carried high-impact variants in our current study: *CUX2, HSPB2, INA, MITF, SCN5A, SGCD,* and *WDR38*. Among these, *INA* was the only gene that carried high-impact variants in more than one independent case (N = 2; Supplementary Table 2).

Table 1. Descriptive statistics of the cohorts.

Cohort	N (M)	Age	PIQ	SWR	NWR	SPELL	IWR	ORTH	PA
Discovery	53 (40)	12	0.17	-2.04	-1.52	-2.30	-2.39	-1.79	-1.25
Replication			PIQ	SWR	NWR	ACC	COMP	RR	
RD	38 (22)	8	-0.10	-0.71	-0.80	-1.05	-1.00	-0.67	
TD	82 (36)	8	0.47	0.97	0.73	0.34	0.27	0.62	
T-stat			3.77	11.21	10.23	11.23	10.12	8.22	
P			1.55E-3	1.61E-19	3.50E-17	2.02E-19	8.84E-17	2.09E-12	

Phenotypic scores are represented as mean z-scores, which have been standardized based on population distributions with mean=100 and SD=15. N: sample size; M: male; Age: mean age at assessment in years; PIQ: performance IQ, SWR: single word reading; NWR: non-word reading; SPELL: single word spelling accuracy; IWR: irregular word reading; ORTH: orthographic coding; PA: phonemic awareness; ACC: NARA-II accuracy; COMP: NARA-II comprehension; RR: NARA-II reading rate; T-stat: absolute t-test statistic; P-value: Bonferroni adjusted for six tests.

The 512 genes identified in our analysis did not include any previously reported candidate genes associated with dyslexia through common (*i.e. KIAA0319* and *DCDC2)* or rare (*i.e. CEP63, DYX1C1, NCAN, ROBO1,* and *SEMA3C*) variants. However, our annotations for disease associations highlighted two different variants in *ZGRF1,* a gene previously implicated in CAS (Peter et al., 2016), in two independent cases. Gene pathway enrichment analysis showed that the top associated pathways were action potential for the biological processes (BP, p_{adj} = 3.55E-6) category, membrane protein complex for the cellular component (CC, p_{adj} = 5.23E-14) category, and adenyl nucleotide binding for the molecular function (MF, p_{adj} = 4.56E-14) category (Supplementary Tables 3–5).

Analyses of gene expression profiling data did not show enrichment for brain expression in any specific regions when testing GTEx v8 general tissue types (Supplementary Table 6) or BrainSpan datasets (Supplementary Tables 7 and 8).

There were 22 genes that presented high-impact variants in at least three independent cases (Supplementary Table 9). The gene with the highest number of high-impact variants was *CFTR*, with six different variants identified in seven individuals. This was followed by *CLDN3* which had the same 7-73769649-G-A variant reported in five unrelated individuals.
The top associations in gene pathways enrichment analysis for these genes were membrane depolarization (BP, p_{adj} = 0.01; Supplementary Table 10), transporter complex (CC, p_{adj} = 4.26E-3; Supplementary Table 11), and high voltage-gated calcium channel activity (MF, p_{adj} = 2.63E-3; Supplementary Table 12). This group of genes did not exhibit specific patterns of brain expression (Supplementary Tables 13–15).

We then conducted a replication analysis for the 22 genes in 38 individuals with reading difficulties (RD replication cases) and in 82 typically developing (TD) controls (Table 1). In the RD replication cases, a gene was considered replicated if at least one high-impact variant was present, even if this involved a different variant from that identified in the discovery cohort. Additionally, our replication criteria required that no variants identified in the discovery and RD cases could be present in the TD group. Under these criteria, five genes showed evidence of replication: *CACNA1D*, *CACNA1G*, *CLDN3*, *CNGB1* and *CP*. An additional 7-73769649-G-A rare allele in *CLDN3* was identified in the RD cases (Table 2).
For three genes (*CACNA1G*, *CACNA1D*, and *CNGB1)*, high-impact variants tended to cluster in adjacent exons and, consequently, in spatially close regions of the resulting protein (Figure 1).



259

Figure 1. Schematic showing high-impact variants in five replicated genes. The location of high-impact variants (red dots) is shown in relation to exons (lower tracks) and protein domains (upper track) for the A) *CLDN3*, B) *CACNA1G*, C) *CACNA1D*, D) *CNGB1* and E) *CP* genes. A) A 2D structure of the single-exon CLDN3 gene shows that the 7-73769649-G-A variant leads to the P134L amino acid change in the third transmembrane (TM3) domain of the protein.

All high impact variants occurred in heterozygous status. One individual carried high impact variants in three of these genes (*CNGB1, CLDN3* and *CACNA1D)* and two individuals carried high impact variants in two genes (*CACNA1D* and *CLDN3; CACNA1G* and *CLDN3).*

We compared reading scores between the carriers and non-carriers of the *CLDN3* variant which showed highest recurrence in the discovery cohort (Supplementary Table 16). On average the carriers of this variant exhibited lower scores on all six reading-related measures. The individual in the RD replication cases who carried the 7-73769649-G-A rare allele exhibited a high PIQ (z-score = 1.13), an extremely low reading scores (*i.e.* SWR z-score = -3; average reading z-scores = -2.23). Their dizygotic twin sibling shared the same variant and did not meet criteria for assignment to either the RD or the TD group. This sibling presented a high PIQ score (z-score = 1.6) and all five reading scores were below the mean (average z-score = -0.68), meeting criteria for mild reading problems.

Finally, we evaluated the segregation patterns of variants in the five replicated genes, for cases in the discovery cohort where family members were available. Siblings had been assessed using the same battery of tests as the cases. Parents had not been assessed systematically, but for some of them self-reported information for dyslexia diagnoses or reading difficulties were available.

No data on family members were available for carriers of variants in the *CACNA1G* and *CP* genes. Only one family was available for *CNGB1* (16-57901371-T-A), two families were available for *CLDN3* (7-73769649-G-A), and one family had variants in three genes (*CNGB1* 16-57901371-T-A, *CLDN3* 7-73769649-G-A and *CACNA1D* 3-53751789-G-A; Figure 2). Overall, the observed segregation patterns were consistent with dominant effects with

292 variable expressivity as all individuals carrying high-impact variants and for whom data were
293 available exhibited some form of reading difficulties.
294



295

296 **Figure 2. Segregation analysis.** Four families were available for segregation analysis of the
297 variants in the five candidate genes. Overall, segregation patterns are consistent with
298 dominant effects with variable expressivity. The phenotypes of the probands and their
299 siblings were defined through a battery of cognitive tests aimed at assessing reading
300 abilities. Parents were not formally assessed, and their phenotypic status was based on self-
301 reported information. Parents who answered "maybe" when asked if they had dyslexia are
302 indicated in grey. A question mark indicates that no information was available for the
303 parents. Mild reading difficulties (striped pattern) in the children were defined as having
304 either at least one of the reading scores lower than 1 SD from the mean or an average score
305 across all reading measures at least 0.25 SD below the mean.

306 **Table 2.** Genes meeting our prioritisation criteria

Gene	Variant	gnomAD AF	CADD score	Discovery N=53	Replication N=38	Control N=82	Max brain Expression**	Nervous system region
CLDN3	7-73769649-G-A	0.0078	33	5	1	0	2.03	Cerebellar Hemisphere
	All variants			**5**	**1**	**1***		
CACNA1G	17-50600739-G-A	0.0034	28	3	1	0	3.86	Cerebellum
	17-50601149-G-A	0.000031	34	1	0	0		
	All variants			**4**	**1**	**0**		
CACNA1D	3-53747393-G-A	0.0000155	34	1	0	0	1.7	Cerebellum
	3-53749301-G-T	.	28.8	1	0	0		
	3-53751789-G-A	0.0000465	34	1	0	0		
	All variants			**3**	**1***	**0**		
CNGB1	16-57897524-C-T	0.0061	34	2	1	0	2.48	Hypothalamus
	16-57901371-T-A	0.0011	31	1	0	0		
	All variants			**3**	**2***	**0**		
CP	3-149178609-C-G	0.0023	27.4	1	1	0	0.87	Spinal cord
	3-149199783-G-A	0.0042	28.3	1	0	0		
	3-149207611-T-C	0.0006	25.8	1	0	0		
	All variants			**3**	**1**	**1***		

307 * variant in the same gene but different from those identified in the discovery cohort; ** maximum observed normalised gene expression across 13 brain regions; CADD =
308 Combined Annotation Dependent Depletion.

Discussion

We report the results of a WES study of dyslexia conducted in a discovery cohort (N = 53) and followed up in a replication cohort (N = 38 RD cases and N = 82 TD controls), representing the largest analysis of this kind conducted to date. All cases and their siblings were assessed in person with a battery of standardised tests. Our findings highlight five replicated genes with high-impact variants detected in 26% (N = 14) individuals of the discovery cohort.

The observation with highest recurrence was a specific rare variant (7-73769649-G-A) in the *CLDN3* gene which was observed in a total of six unrelated cases across the discovery and RD cohorts (N_{total} = 91). This corresponds to an allele frequency of 3.3%, representing a four-fold increase compared to the frequency of 0.8% reported for this variant in the gnomAD samples of European ancestry. Moreover, this variant was not observed in the TD controls, minimising a potential population structure effect caused by a recruitment bias within the UK.

CLDN3 is a single exon gene spanning 1274 bases in total at 7q11.23, within the critical region deleted in Williams syndrome, a developmental disorder characterized by learning difficulties, distinctive facial features, and cardiovascular problems (41). This gene encodes Claudin-3, a protein expressed in different epithelia with roles for the formation of tight junctions and the blood-brain-barrier (42). Depletion of Cldn3 has been shown to lead to neural tube defects using a chick embryos model system. Targeted analysis of *CLDN* genes in 152 patients with spinal neural tube defects (NTDs) identified eleven variants, including a A128T missense variant in *CLDN3*. Overexpression of the *CLDN3* A128T variant in chick embryos resulted in a significant increase in NTDs in this model (43). The 7-73769649-G-A variant identified in this study results in a P134L amino acid change, which, like A128T, is located in the third transmembrane (TM3) domain of Claudin-3. In both Claudin-3 and Claudin-5, the TM3 domain is critical for tight junctions assembly, as demonstrated by studies in HEK293 cells (44). These observations, combined with a high CADD score (= 33; Table 2), predict that the 7-73769649-G-A variant is likely to impact the function of the CLDN3 protein.

Among the five replicated genes were two members of the voltage-gated calcium channel (VGCC) family, *CACNA1D* and *CACNA1G*. VGCC genes are critical for proper brain function,

mediating essential calcium-dependent processes such as gene transcription, neurotransmitter release, and neurite outgrowth (45). Both *CACNA1D* and *CACNA1G,* which show high level of expression in the cerebellum, have been previously implicated in neurodevelopmental disorders. *CACNA1D* variants have been associated with ASD, global developmental delay and other neurodevelopmental conditions (46,47). *CACNA1G* variants have been associated with infantile-onset syndromic cerebellar ataxia (48), severe neurodevelopmental delay, epilepsy (47) and intractable seizures (49). Furthermore, we observed high-impact variants in another VGCC gene, *CACNA1C*, in two independent cases from the discovery cohort (Supplementary Table 2). No variants in *CACNA1C* were observed in the TD group.

For the remaining two replicated genes, there is less evidence for a role in neurodevelopment. The *CNGB1* gene encodes the cyclic nucleotide-gated channel beta 1 protein, which is a subunit of the rod photoreceptor cyclic nucleotide-gated channels. These channels ensure a flow of ions into the rod photoreceptor outer segment in response to light-induced changes in intracellular cyclic GMP levels. *CNGB1* variants are associated with retinitis pigmentosa, a degenerative eye disease that affects photoreceptor function (50). *CP* encodes ceruloplasmin, a major copper-carrying protein in the blood. Variants in the *CP* gene can lead to aceruloplasminemia, a rare genetic disorder characterised by iron accumulation in the brain and other organs which can result in neurological and systemic symptoms (51). Elevated levels of iron in the cortical speech motor network have been reported in people who stutter (52).

In terms of intragenic localisation, the variants detected for *CACNA1D, CACNA1G* and *CNGB1* clustered within restricted regions of each gene. Specifically, the three *CACNA1D* (one novel and two ultra-rare) variants, cluster within exons 26-28, while all two *CNGB1* variants cluster within the cyclic nucleotide-monophosphate (c-NMP) binding domain (Figure 1).

We did not detect variants in genes previously identified in GWAS, WES, or candidate gene association studies related to dyslexia, and none of the five genes highlighted in our study

have been previously implicated in dyslexia. This underscores the highly polygenic nature of the condition.

However, our annotations highlighted two unrelated individuals with distinct variants in *ZGRF1* (Supplementary Table 2), one of which was the same variant (4-112585555-C-T) previously reported in CAS, a language-related condition (40). The same 4-112585555-C-T variant was present also in a TD control and therefore studies of larger cohorts are required to clarify the role of this gene in language-related conditions.

The gene with highest number of recurrent variants observed in the discovery cohort was *CFTR*, which was not retained as a gene of interest because one of the variants detected in the discovery sample was also present in the TD group. Variants in *CFTR* are known to cause cystic fibrosis, and its role in neurodevelopment is not well established. However, early studies reported a significant linkage signal for language impairment at the *CFTR* locus (53). These two examples highlight the importance of including controls with relevant phenotypic measures to highlight potential false positives. Conversely, the likelihood of false negatives was increased by the relatively small size of our sample, requiring stringent filtering criteria for pathogenicity predictions. WES analyses in larger cohorts will enable a more systematic evaluation of the role of rare variants to dyslexia, such as for the spectrum of *CFTR* variants.

The detailed cognitive assessment of cases and their family members allowed us to further evaluate the phenotypic effects of the top five genes and variants. Although limited to four families, the segregation patterns were consistent with dominant effects for the three genes that were analysed. All variant carriers with available phenotypic data exhibited some degree of reading problems. In family 4, the *CNGB1* risk variant is transmitted from the father, who self-reported reading problems, to the proband but not to the sibling. The sibling presents with mild reading difficulties suggesting that other risk factors contribute might be present in this family. The patterns in family 10 and 18 are consistent with a dominant effect of the *CLDN3* 7-73769649-G-A variant on dyslexia and/or reading difficulties. In family 18, the variant is transmitted from the father with self-reported reading difficulties to three siblings with either dyslexia (PIQ z-score = 1.5; SWR z-score = -2.2;

average reading measures z-score = -2.51) or mild reading problems. One of the siblings with a mild phenotype has a high PIQ (z-score = 1.7) and an average z-score across the reading measures of -0.54. The other sibling does not have a PIQ measure but presents with a high verbal IQ (z-score = 1.6) and an average z-score across the reading measures of -0.4. The fourth sibling does not have the variant and is a good reader (SWR z-score = 1.3). Finally, in family 32, the proband carries three risk variants and presents exceptionally low reading scores (average across six reading tasks = -2.5 SD) despite having a PIQ above the mean (z-score = 0.1). The sibling, who shares only the *CLDN3* variant out of the three, presents a mild phenotype characterised by a high PIQ (z-score = 2.3) and low z-scores on specific reading tasks (IWR = -0.61, ORTH = -1.16).

A large discrepancy between PIQ and reading scores were observed for the carrier of the *CLDN3* variant identified in the RD replication cases (PIQ z-score = 1.13; average reading z-scores = -2.23) and the carrier's sibling (PIQ z-score = 1.6; average reading z-scores = -0.68) who shared the same variant. Overall, such patterns support a role for these rare variants in dyslexia and varying degrees of reading difficulties.

The phenotypic variability suggests that additional factors modulate the effects of these variants. It is worth nothing that, in the discovery cohort, the other two carriers of the *CLDN3* variant for whom we had no family data, also carried a high impact variant in either *CACNA1D* or *CACNA1G*. This suggests that the effect of the *CLDN3* variant on reading abilities could potentially be modulated by other rare risk variants. The phenomenon of variable expressivity, as well as incomplete penetrance, has been reported for most complex traits, including psychiatric and cognitive phenotypes (24). These phenomena are likely to reflect the interaction of genetic, environmental, and lifestyle factors in influencing phenotypic outcomes. Typically, rare variants discovered in clinical cohorts with specific phenotypic characteristics tend to be associated with milder manifestations in the general population, likely due to the absence of such interacting risk factors.

In conclusion, this study advances our understanding of potential roles of rare genetic variants in dyslexia. We identified five novel candidate genes. These include *CLDN3* which plays several key functions in neurodevelopmental processes. Notably, a specific variant in

CLDN3 was identified in six independent cases. Two other genes, *CACNA1D* and *CACNA1G*, members of the VGCC gene-family, are involved in neuronal excitability, and have previously been linked to other neurodevelopmental conditions. While our findings do not overlap with previously reported dyslexia-associated genes, they align with the established role of VGCC genes in psychiatric and neurodevelopmental conditions. We extend the significance of this pathway to dyslexia, suggesting that VGCCs may contribute to its aetiology and linking these genes to shared mechanisms across neurodevelopmental traits. Additionally, genes such as *CFTR* and *CACNA1C*, which were excluded based on our stringent filtering criteria, may represent potential candidates for future investigations.

These findings underscore the importance of systematic WES or WGS analysis in larger, well-characterised cohorts to identify additional genetic factors and further advance our understanding of the neurobiology underlying dyslexia.

Code availability

Code used in the current study to analyse the data can be found at https://github.com/kmarianski/DyslexiaWES_CLDN3

Acknowledgements

We would like to thank the participants, their families, recruiters and health-care staff involved in collection of the data.

Funding

KM is supported by a Medical Research Scotland scholarship [PhD-50010-2019]. This work was supported by Action Medical Research Action/The Chief Scientist Office (CSO), Scotland grant [GN2614] and a Royal Society Grant [UF100463]. Bioinformatic analysis was conducted on the UK's Crop Diversity Bioinformatics HPC which is funded by the BBSRC [BB/S019669/1]. The recruitment of the Discovery cohort was supported by Wellcome Trust Grants [076566/Z/05/Z and 075491/Z/04] and a Waterloo Foundation Grant [797–1720]. Recruitment and analysis of the Replication cohorts was supported by Wellcome Trust

Programme Grants [082498], and European Research Council Advanced Grant [694189]. SEF is supported by the Max Planck Society.

References

1. Erbeli F, Rice M, Paracchini S. Insights into dyslexia genetics research from the last two decades. Brain Sciences 2022, Vol 12, Page 27. 2021 Dec;12(1):27–27.

2. Arnett AB, Pennington BF, Peterson RL, Willcutt EG, DeFries JC, Olson RK. Explaining the sex difference in dyslexia. Journal of Child Psychology and Psychiatry and Allied Disciplines. 2017 Jun, 58(6), 719-727

3. Daucourt MC, Erbeli F, Little CW, Haughbrook R, Hart SA. A Meta-Analytical review of the genetic and environmental correlations between reading and Attention-Deficit/Hyperactivity Disorder symptoms and reading and math. Scientific Studies of Reading. 2020 Jan 2;24(1):23–56.

4. Snowling MJ, Hayiou-Thomas ME, Nash HM, Hulme C. Dyslexia and Developmental Language Disorder: comorbid disorders with distinct effects on reading comprehension. Journal of Child Psychology and Psychiatry. 2020;61(6):672–80.

5. Snowling MJ, Melby-Lervåg M. Oral language deficits in familial dyslexia: A meta-analysis and review. Psychological Bulletin. 2016;142(5):498–545.

6. Paracchini S, Scerri TS, Monaco AP. The genetic lexicon of dyslexia. Annual Review of Genomics and Human Genetics. 2007/04/21 ed. 2007;8:57–79.

7. Doust C, Fontanillas P, Eising E, Gordon SD, Wang Z, Alagöz G, et al. Discovery of 42 genome-wide significant loci associated with dyslexia. Nature Genetics. 2022 Nov;54(11):1621–9.

8. Eising E, Mirza-Schreiber N, de Zeeuw EL, Wang CA, Truong DT, Allegrini AG, et al. Genome-wide analyses of individual differences in quantitatively assessed reading- and language-related skills in up to 34,000 people. Proceedings of the National Academy of Sciences. 2022 Aug 30;119(35):e2202764119.

9. Momozawa Y, Mizukami K. Unique roles of rare variants in the genetics of complex diseases in humans. Journal Human Genetics. 2021 Jan;66(1):11–23.

10. Wang T, Zhao PA, Eichler EE. Rare variants and the oligogenic architecture of autism. Trends in Genetics. 2022 Sep 1;38(9):895–903.

11. Howrigan DP, Rose SA, Samocha KE, Fromer M, Cerrato F, Chen WJ, et al. Exome sequencing in schizophrenia-affected parent–offspring trios reveals risk conferred by protein-coding de novo mutations. Nature Neuroscience. 2020 Feb;23(2):185–93.

12. Forstner AJ, Fischer SB, Schenk LM, Strohmaier J, Maaser-Hecker A, Reinbold CS, et al. Whole-exome sequencing of 81 individuals from 27 multiply affected bipolar disorder families. Translational Psychiatry. 2020 Feb 4;10(1):57.

13. Eising E, Carrion-Castillo A, Vino A, Strand EA, Jakielski KJ, Scerri TS, et al. A set of regulatory genes co-expressed in embryonic human brain is implicated in disrupted speech development. Molecular Psychiatry. 2019 Jul;24(7):1065–78.

14. Hildebrand MS, Jackson VE, Scerri TS, Van Reyk O, Coleman M, Braden RO, et al. Severe childhood speech disorder: Gene discovery highlights transcriptional dysregulation. Neurology. 2020;94(20):e2148–67.

15. Kaspi A, Hildebrand MS, Jackson VE, Braden R, van Reyk O, Howell T, et al. Genetic aetiologies for childhood speech disorder: novel pathways co-expressed during brain development. Molecular Psychiatry. 2023 Apr;28(4):1647–63.

16. Rajagopal VM, Duan J, Vilar-Ribó L, Grove J, Zayats T, Ramos-Quiroga JA, et al. Differences in the genetic architecture of common and rare variants in childhood, persistent and late-diagnosed attention-deficit hyperactivity disorder. Nature Genetics. 2022 Aug;54(8):1117–24.

17. Chen XS, Reader RH, Hoischen A, Veltman JA, Simpson NH, Francks C, et al. Next-generation DNA sequencing identifies novel gene variants and pathways involved in specific language impairment. Scientific Reports. 2017;7:46105–46105.

18. Devanna P, Chen XS, Ho J, Gajewski D, Smith SD, Gialluisi A, et al. Next-gen sequencing identifies non-coding variation disrupting miRNA-binding sites in neurological disorders. Molecular Psychiatry. 2018;23(5):1375–84.

19. Villanueva P, Nudel R, Hoischen A, Fernández MA, Simpson NH, Gilissen C, et al. Exome sequencing in an admixed isolated population indicates NFXL1 variants confer a risk for specific language impairment. Abrahams BS, editor. PLoS Genetics. 2015 Mar;11(3):e1004925–e1004925.

20. Taipale M, Kaminen N, Nopola-Hemmi J, Haltia T, Myllyluoma B, Lyytinen H, et al. A candidate gene for developmental dyslexia encodes a nuclear tetratricopeptide repeat domain protein dynamically regulated in brain. Proceedings of the National Academy of Sciences. 2003;100(20):11553–8.

21. Einarsdottir E, Svensson I, Darki F, Peyrard-Janvid M, Lindvall JM, Ameur A, et al. Mutation in CEP63 co-segregating with developmental dyslexia in a Swedish family. Human Genetics. 2015;134(11–12):1239–48.

22. Einarsdottir E, Peyrard-Janvid M, Darki F, Tuulari JJ, Merisaari H, Karlsson L, et al. Identification of NCAN as a candidate gene for developmental dyslexia. Scientific Reports. 2017 Aug 24;7(1):9294.

23. Carrion-Castillo A, Estruch SB, Maassen B, Franke B, Francks C, Fisher SE. Whole-genome sequencing identifies functional noncoding variation in SEMA3C that cosegregates with dyslexia in a multigenerational family. Human Genetics. 2021 Aug 1;140(8):1183–200.

24. Kingdom R, Wright CF. Incomplete penetrance and variable expressivity: from clinical studies to population cohorts. Frontiers in Genetics. 2022 Jul 25;13:920390.

25. Scerri TS, Macpherson E, Martinelli A, Wa WC, Monaco AP, Stein J, et al. The DCDC2 deletion is not a risk factor for dyslexia. Translational Psychiatry. 2017 Jul 25;7(7):e1182–e1182.

26. Elliot CD Murray, DJ, and Pearson, LS. British Abilities Scales. NFER-Nelson, Windsor, UK. 1983.

27. Castles A, Coltheart M. Varieties of developmental dyslexia. Cognition. 1993;47(2):149–80.

28. Frederickson N Frith, U, Reason, R. Phonological assessment battery (PhAB). Windsor: NFER-Nelson. 1997.

29. Olson R Forsberg, H, Wise, B,& Rack, J. Measurement of word recognition, orthographic, and phonological skills. In G. R. Lyon (Ed.), Frames of reference for the assessment of learning disabilities: New views on measurement issues. Paul H Brookes Publishing Co. 1994.

30. Wechsler D, Golombok J, Rust J. WISC-III UK Wechsler intelligence scale for children: UK manual. Sidcup, UK: The Psychological Corporation; 1992.

31. Wilson AC, Bishop DVM. Resounding failure to replicate links between developmental language disorder and cerebral lateralisation. PeerJ. 2018;6:e4217.

32. Torgesen JK, Rashotte CA, Wagner RK. TOWRE: Test of word reading efficiency. Pro-ed Austin, TX; 1999.

33. Neale MD. Neale Analysis of Reading Ability: Reader. Third Edition. ACER Press, Australian Council for Educational Research Limited, 19 Prospect Hill Road, Camberwell, Melbourne, Victoria 3124, Australia; 1999.

34. Goodman R, Ford T, Richards H, Gatward R, Meltzer H. The Development and Well-Being Assessment: description and initial validation of an integrated assessment of child and adolescent psychopathology. Journal of Child Psychology and Psychiatry. 2000/08/18 ed. 2000;41(5):645–55.

35. Bolger AM, Lohse M, Usadel B. Trimmomatic: a flexible trimmer for Illumina sequence data. Bioinformatics. 2014 Aug 1;30(15):2114–20.

562 36. Poplin R, Chang PC, Alexander D, Schwartz S, Colthurst T, Ku A, et al. A universal SNP and
563 small-indel variant caller using deep neural networks. Nature Biotechnology. 2018
564 Nov;36(10):983–7.

565 37. Wang K, Li M, Hakonarson H. ANNOVAR: functional annotation of genetic variants from
566 high-throughput sequencing data. Nucleic Acids Research. 2010 Sep;38(16):e164.

567 38. Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, et al. Standards and guidelines
568 for the interpretation of sequence variants: a joint consensus recommendation of the
569 American College of Medical Genetics and Genomics and the Association for Molecular
570 Pathology. Genetics in Medicine. 2015 May;17(5):405–24.

571 39. Lonsdale J, Thomas J, Salvatore M, Phillips R, Lo E, Shad S, et al. The Genotype-Tissue
572 Expression (GTEx) project. Nature Genetics. 2013 Jun;45(6):580–5.

573 40. Peter B, Wijsman EM, Nato AQ, University of Washington Center for Mendelian
574 Genomics, Matsushita MM, Chapman KL, et al. Genetic candidate variants in two
575 multigenerational families with childhood apraxia of speech. Cai T, editor. PLoS ONE.
576 2016 Apr 27;11(4):e0153864.

577 41. Morris CA, Mervis CB. Williams Syndrome. In: Cassidy and Allanson's Management of
578 Genetic Syndromes . John Wiley & Sons, Ltd; 2021 . p. 1021–38.
579 https://onlinelibrary.wiley.com/doi/abs/10.1002/9781119432692.ch63

580 42. Günzel D, Yu ASL. Claudins and the modulation of tight junction permeability.
581 physiological review. 2013 Apr;93(2):525–69.

582 43. Baumholtz AI, De Marco P, Capra V, Ryan AK. Functional validation of CLDN variants
583 identified in a neural tube defect cohort demonstrates their contribution to neural tube
584 defects. Frontiers in Neuroscience. 2020
585 https://www.frontiersin.org/journals/neuroscience/articles/10.3389/fnins.2020.00664/f
586 ull

587 44. Rossa J, Ploeger C, Vorreiter F, Saleh T, Protze J, Günzel D, et al. Claudin-3 and Claudin-5
588 protein folding and assembly into the tight junction are controlled by non-conserved
589 residues in the transmembrane 3 (TM3) and extracellular loop 2 (ECL2) segments *.
590 Journal of Biological Chemistry. 2014 Mar 14;289(11):7641–53.

591 45. Simms BA, Zamponi GW. Neuronal voltage-gated calcium channels: structure, function,
592 and dysfunction. Neuron. 2014 Apr 2;82(1):24–45.

593 46. Hofer NT, Tuluc P, Ortner NJ, Nikonishyna YV, Fernándes-Quintero ML, Liedl KR, et al.
594 Biophysical classification of a CACNA1D de novo mutation as a high-risk mutation for a
595 severe neurodevelopmental disorder. Molecular Autism. 2020;11(1):4.

596 47. Rajakulendran S, Hanna MG. The role of calcium channels in epilepsy. Cold Spring Harb
597 Perspect Med. 2016 Jan 4;6(1):a022723.

598 48. Barresi S, Dentici ML, Manzoni F, Bellacchio E, Agolini E, Pizzi S, et al. Infantile-onset
599 syndromic cerebellar ataxia and CACNA1G mutations. Pediatric Neurology. 2020
600 Mar;104:40–5.

601 49. Kunii M, Doi H, Hashiguchi S, Matsuishi T, Sakai Y, Iai M, et al. De novo CACNA1G variants
602 in developmental delay and early-onset epileptic encephalopathies. Journal of the
603 Neurological Sciences. 2020 Sep;416:117047.

604 50. Alshamrani AA, Raddadi O, Schatz P, Lenzner S, Neuhaus C, Azzam E, et al. Severe
605 retinitis pigmentosa phenotype associated with novel CNGB1 variants. American Journal
606 of Ophthalmology Case Reports. 2020 Sep;19:100780.

607 51. Yoshida K, Furihata K, Takeda S, Nakamura A, Yamamoto K, Morita H, et al. A mutation in
608 the ceruloplasmin gene is associated with systemic hemosiderosis in humans. Nature
609 Genetics. 1995 Mar;9(3):267–72.

610 52. Cler GJ, Krishnan S, Papp D, Wiltshire CEE, Chesters J, Watkins KE. Elevated iron
611 concentration in putamen and cortical speech motor network in developmental
612 stuttering. Brain. 2021 Nov 29;144(10):2979–84.

613 53. O'Brien EK, Zhang X, Nishimura C, Tomblin JB, Murray JC. Association of Specific
614 Language Impairment (SLI) to the Region of 7q31. The American Journal of Human
615 Genetics. 2003 Jun 1;72(6):1536–43.

616

617